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A hypothesis is put forward on the nature of the endothclium-derived relaxing factor (EDRF) which is released from vascular cndothclial cells 
by acetylcholine. bradykinin and other agonists. It is suggested that EDRF is a nitrosyl iron complex with low-molecular thiol ligands. most 
probably with cysteinc. Its active principle is nitric oxide (NO). This free radical is stabilized by inclusion into the iron complex. which promotes 
NO transfer within the ccl1 and between cells. Subsequent release of WO from these complescs results from thiol group oxidation. 
Endothelium-dcrivcd relaxing factor; Nitric oxide: Nitrosyl non-hcme iron conrples: Free iron 
1. INTRODUCTION 
Furchgott and Zawadsky discovered in 1980 that ace- 
tylcholine. among other substances. stimulates the va- 
scular endothelium to release a factor capable of relax- 
ing blood vessels, named endothelium-derived relaxing 
factor (EDRF) [IJ. Its nature remains unclear. Most 
researchers suggest that the active principle of EDRF 
is nitric oxide (NO) [2-121. Both EDRF and NO relax 
the vascular smooth muscle through the stimulation of 
soluble guanylate cyclase [13.14]. They share similar 
half-lifes in media containing superoxide radicals 
[3.4.14]. When reacting with Ozl radicals. both EDRF 
and NO are transformed to nitrite and nitrate anions 
[15.163. 
Despite these similarities, EDRF and NO are not 
identical. EDRF is more potent and long-lasting as a 
vasodilator [IO. 121. Unlike NO. EDRF is not able to 
produce paramagnetic nitrosyl complexes with heme 
and non-heme iron [17.18]: it can no: be evaporated 
from an aqueous solution [12.19]: it is trapped by some 
resins [20]. Fina1l.y. there is evidence that EDRF does 
not relax non-vascular smooth muscles. unlike NO 
which easily induces their relaxation [2 1.221. 
.~/)h,‘c~~il,/iofrs~ DNIC. dinitrosyl irori complex: DETC. diccthyldithio- 
carb:miarc anion: EDRF. cndothclium-derived rcl:ixing factor: ESR, 
clcctron spin rcsonancc; MNIC. mononirrosyl iron complcs: NO. 
nitric oxidc 
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For these reasons most investigators suggest that 
EDRF is a labile nitroso compoundcapable of releasing 
nitric oxide when interacting with vascular smooth mus- 
cle cells [3.8,10.12.22-241. It is suggested that NO in- 
cluded in this compound is protected from various in- 
tracellular reagents. thus increasing its cellular life-time. 
At present. the most popular candidate for EDRF is an 
S-nitrnsqthiol. with the NO counterpart being most 
probably the thiol ligands. cysteine or glutathione 
[23.24]. Some data show similar physico-chemical char- 
acteristics and vasodilatory activities between EDRF 
and S-nitrosothiols [IO]. Nevertheless. this idea seems 
unrealistic. Its weak point is the very low stability of 
nitrosothiols in aqueous medium within the neutral pH- 
range. The nitrosothiols are stable in acid solutions 
only. Thus it is necessary to speculate that they are 
formed and stored in special vacuoles with a highly acid 
inner phase [24]. This condition seems to be quite im- 
probable and artificial. 
2. PROPOSAL 
This instability may be overcome by proposing that 
EDRF contains not only NO and thiols. bu; also iron. 
i.e. EDRF is a nitrosyl-non-heme-iron complex with 
thiols. These complexes were found in cells and animal 
tissues R long time ago [25-311. Such complexes are 
sufficiently stable in neutral solution. Their structure 
and production conditions have been thoroughly stu- 
died [32-351. They are dinitrosyl iron complexes 
(DNIC) with protein paired thiol groups or similar low- 
molecular compnzlds. Thpse species are param.agnetic. 
their electron spin S = l/2. an unpaired electron being 
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localized mainly at the iron atom with electron configu- 
ration d’ (informal valence state Fe(l)). The nitrosyl 
groups exist in these complexes as nitrosonium-cations 
NO’ [32]. They give an electronspin resonance (ESR) 
signal with axial anisotropy of g-tensor g, = 2.037, 
gll = 2.012, g,,. = 2.03 [32] and are usually named 
‘2.03 complexes’, according to their g;,, value. 
3. WHAT ARE THE FACTS AND EVIDENCE 
FOR THIS HYPOTHESIS? 
1. The existence of 2.03 complexes in animal cells and 
tissues, when treated with nitric oxide in vitro and in 
vivo, as mentioned above. Recently. it was shown that 
2.03 complexes occur also in activated macrophages 
which are capable of producing nitric oxide from L- 
arginine [36,37], the latter being the precursor of EDRF 
[5.6]. 
2. The presence in cells and tissues of two forms of 
2.03 complexes, i.e. those bound to protein through 
their RS-groups, and those containing low-molecular 
thiol ligands, cysteine or reduced glutathione [38]. Pro- 
tein 2.03 complexes are more stable, with the equili- 
brium distribution of Fe(NO),-groups between low- 
molecular and protein complexes strongly shifted to- 
wards the latter [38]. Nevertheless. the inclusion of small 
quantities of Fe(NO),-groups into low-molecular 2.03 
complexes provides their transfer within and between 
the cells. The existence of such a transfer is shown by 
the behaviour of protein 2.03 complexes after their in- 
jection into the blood of rats in vivo. After IO-20 min, 
the same complexes are found not only in the blood, but 
also in various tissues of these animals [39]. In model 
experiments on Fe(NO),-transfer between two protein 
solutions separated by an artificial membrane. it was 
shown that such a transfer occurs in the presence of 
low-molecular species capable of binding Fe(NO),-gro- 
ups. These findings suggest that DNIC with small li- 
gands may be identical to EDRF, released from endot- 
helial cells and acting on neighbouring smooth muscle 
cells. Their thiol groups can be easily oxidized. which 
releases iron and nitric oxide. 
At lower cysteine levels the DNIC with this ligand 
form dimeric and higher structures in aqueous solu- 
tions. similar to the red and black Roussin’s salts 
[40,41]. This, if EDRF is the nitrosyl iron complex with 
cysteine, it can be in a dimeric (or polymeric) form. 
3. It is noteworthy that cysteine is released from acti- 
vated endothelial cells producing EDRF [42], and that 
cells release iron when treated with nitric oxide [43.44]. 
1 predict that iron will be released from the cells produ- 
cing EDRF or nitric oxide as well. 
It is suggested that iron released from the NO-treated 
cells is derived from active sites of FeS-proteins 
[36,37,43-461. In my opinion, the main source of iron 
is the loosely bound non-hcme iron, the so-called free 
iron [47]. This iron forms 2.03 complexes [47-49] and 
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it is released from the cells in these low-molecular spe- 
cies. 
4. 2.03 complexes display hypotensive properties, 
they act as vasodilators in isolated blood vessels and 
inhibit platelet aggregation [39, 50-521. These activities 
are due to nitric oxide. The two-phase kinetics of their 
effect has been found in animals, both narcotized or 
conscious. After a single dose of low-molecular 2.03 
complexes. a fast initial decrease of arterial pressure is 
followed by a Iong-lasting (several hours) and steady 
hypotension in narcotized animals. or by a slow reco- 
very (during 1.5-2 hours) in conscious animals. During 
the steady-state phase the main fraction of Fe(NO), 
groups has been transferred from low-molecular to pro- 
tein thiol groups. The formed protein 2.03 complexes 
provide a long-lasting hypotensive effect by gradually 
releasing nitric oxide, i.e. they act as a molecular storage 
of NO. The fast initial decrease in arterial pressure may 
be due to NO release from the small low-molecular 
fraction of DNIC which did not transfer their Fe(NO), 
groups to protein. 
Similar fast hypotensive effects may be achieved by 
protein 2.03 complexes when treated in the organism by 
diethyldithiocarbamate (DETC) [39]. With Fe” and 
NO this anion produces the paramagnetic mononitrosyl 
iron complexes (MNIC). These complexes are much 
more stable than 2.03 complexes. DETC removes from 
each of them a single iron ion and a single NO molecule. 
producing MNIC [53]. The unconsumed NO is then 
released in free form and induces a strong but transient 
hypotensive effect. 
The above mentioned suggestion concerning the na- 
ture of EDRF is a working hypothesis requiring detai- 
led experimental testing. First. the vasodilating proper- 
ties of EDRF and 2.03 complexes should be compared; 
second, using the ESR technique, we need to verify 
whether EDRF and 2.03 complexes are really identical. 
Until recently, no data have been obtained on EDRF 
paramagnetism [I8,241, probably due to the low concen- 
tration of EDRF in solution - about 10mn M [lo]. 
We showed recently [54] that NO-synthase in the cy- 
tosol from endothelial cells produces directly free NO. 
Apparently, the same process takes place in intact cells. 
Free nitric oxide would then bind to iron and thiol 
ligands forming EDRF. This is a way to stabilize NO 
in cells, and to provide both NO-transfer in tissues and 
its release in the active free state. 
/ic’~rro~~,/~~ljic~~~~~t~~ This hypothesis was dcvclopcd in its final form due 
to useful discussions with P. Mordvintccv during our work al the 
Institute ol‘ Applied Physiology. Frciburg, Germany. I m gratcf’ul to 
him for his criticism and cncouragemcnt. 
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